| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Research Abstract |
1. The expression of the genes of Bcl-2 and Bax may be useful prognostic factor in head and neck cancer patients.
2. The possibility that 5-FU may enhance the T cell-stimulatingability of dendritic cells via regulation of the expression of PD-L1 and PD-L2, and that the combination therapy of DC-based cancer vaccine with 5-FU may elicit better anti-tumor efficacy than only vaccination.
3. OK-432-based immunotherapy significantly enhanced therapeutic effects of chemoradiotherapy in patients with oral squamous cell carcinoma, but also elucidating mechanism of synergic effect of the immuno-chemoradiotherapy that 5-FU and radiation enhanced OK-432-induced Th1 response mediated by inhibition of expression of SOCS1 and SOCS3genes.
|
